-
Prevention strategies for all: Launch of the 2025 Canadian HIV PEP & PrEP Guideline
Led by Dr. Darrell Tan and supported by the CTN+, this document provides the most update-to-date evidence for…
-
A call for community engagement: Exploring the harms and benefits of molecular HIV surveillance
“The first letter in HIV stands for Human,” writes Dr. Alexander McClelland in a co-authored 2020 paper outlining…
-
Communities teaching communities: A framework for Indigenous community development
With community partners across Alberta and Saskatchewan, the DRUM & SASH team is building a knowledge base to…
-
Putting data into action: How CTN researchers track, prevent, and manage HIV in infants
The Canadian Pediatric and Perinatal HIV/AIDS Research Group is a collection of clinicians and researchers that form the…
-
Everyone ages differently: Cardiovascular disease and HIV
The CTN’s HIV and Aging Cohort Study aims to understand how HIV can affect the development of heart…
-
Age, altruism, or a long-term view: Why do people living with HIV get the COVID-19 vaccine?
Understanding COVID-19 vaccine confidence in people living with HIV in Canada
-
CTN study tests new drug for the first time in people living with HIV
The drug works against CMV, a common virus that may be a main cause of inflammation and health…
-
New research comparing HIV medications set to change international recommendations
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
-
Here’s what we know about COVID-19 & HIV
Many questions remain about COVID-19 and what it means for people living with HIV. We explore the research…
